Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Department of Drug Development and Innovation (D3i)

3 abstracts

Abstract
EXPRESS study: A trial exploring the association of low level of genomic alteration with exceptional and unexpected response to targeted therapies in patients with advanced solid tumors.
Org: Institut Curie Paris, Paris Saclay University & Gustave Roussy, Digestive Surgery Department, Centre d'Oncologie de Gentilly, Hopital Privé de la Loire,
Abstract
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
Org: Institut Curie, Saint Cloud, France, Curie Institute, Department of Drug Development and Innovation (D3i),
Abstract
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Org: Cliniques Universitaires Saint-Luc, Department of Drug Development and Innovation (D3i), Institut Curie, Saint Cloud, France, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, University of Milano, European Institute of Oncology, Division of Early Drug Development,